IP Library Granted Patent US 7,524,652
Granted Patent B2
US 7,524,652 · App. 11/168,592 · Granted Apr 28, 2009

Automated process for detecting the presence of a target nucleic acid in a sample

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,524,652
App. No.
11/168,592
Granted
Apr 28, 2009
Kind
B2
Abstract

An automated process performed in an analyzer for detecting the presence of a target nucleic acid in a sample. The process includes separating the target nucleic acid from other material present in the sample, performing an amplification reaction to produce an amplification product indicative of the presence of the target nucleic acid in the sample, and detecting the amplification product. The amplification reaction can be performed in an open receptacle vessel, such as a test tube.

Claims (27)

1. A process for detecting the presence of a target nucleic acid in a sample containing the target nucleic acid, the process comprising performing the automated steps of:

(a) immobilizing the target nucleic acid on a solid support comprising a magnetically-responsive particle;

(b) subjecting the solid support to a magnetic field and aspirating non-immobilized components of the sample;

(c) performing an amplification reaction using the target nucleic acid immobilized in step (a) to produce an amplification product indicative of the presence of the target nucleic acid in the sample; and

(d) detecting the amplification product of step (c) as an indication of the presence of the target nucleic acid in the sample,

wherein the steps of the process are performed in a self-contained analyzer.

2. The process of claim 1 further comprising washing the solid support one or more times with a wash solution after aspirating the the non-immobilized components of the sample during step (b).

3. The process of claim 1 , wherein the non-immobilized components of the sample include non-target nucleic acid.

4. The process of claim 1 further comprising the step of hybridizing a capture probe to the target nucleic acid prior to step (a).

5. The process of claim 1 , wherein the amplification product is a nucleic acid sequence that is the same as or complementary to a sequence of the target nucleic acid.

6. The process of claim 5 further comprising contacting the amplification product with a probe that hybridizes to the amplification product, wherein the amplification product is detected in step (d) by detecting the probe hybridized to the amplification product.

7. The method of claim 6 , wherein the probe includes a detectable label.

8. The process of claim 5 , wherein the amplification reaction is selected from the group consisting of a polymerase chain reaction, a strand displacement amplification, a ligase chain reaction, and a transcription-associated amplification.

9. A process for detecting the presence of a target nucleic acid in a sample containing the target nucleic acid, the process comprising performing the automated steps of:

(a) immobilizing the target nucleic acid on a solid support comprising a magnetically-responsive particle;

(b) subjecting the solid support to a magnetic field and aspirating non-immobilized components of the sample;

(c) moving the target nucleic acid immobilized in step (a) into a temperature-controlled chamber of an incubator housed within a self contained analyzer;

(d) in the chamber, performing an amplification reaction to produce an amplification product indicative of the presence of the target nucleic acid in the sample; and

(e) detecting the amplification product of step (d) as an indication of the presence of the target nucleic acid in the sample,

wherein the steps of the process are performed in the self-contained analyzer.

10. The process of claim 9 , wherein the non-immobilized components of the sample include non-target nucleic acid.

11. The process of claim 9 , wherein the amplification product is a nucleic acid sequence that is the same as or complementary to a sequence of the target nucleic acid.

12. The process of claim 11 further comprising contacting the amplification product with a probe that hybridizes to the amplification product, wherein the amplification product is detected in step (e) by detecting the probe hybridized to the amplification product.

13. The method of claim 12 , wherein the probe includes a detectable label.

14. The process of claim 11 , wherein the amplification reaction is selected from the group consisting of a polymerase chain reaction, a strand displacement amplification, a ligase chain reaction, and a transcription-associated amplification.

15. The process of claim 9 , wherein steps (a) and (d) are performed at separate stations within a housing of the analyzer.

16. The process of claim 15 , wherein the stations are located on a processing deck.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2008
From: AMMANN, KELLY G.; BURNS, RALPH E.; HANSBERRY, ERNEST V.; HORNER, GLENN A.; JAKUB, CHERYL A.; KLING, JOHN E.; NIEGLOS, DONALD J.; SCHNEIDER, ROBERT E.; SMITH, ROBERT J.
To: GEN-PROBE INCORPORATED
Reel/Frame 021730/0869 →